What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

6:14PomKlementieffasMantis,Groot(voicedbyVinDiesel),ChrisPrattasPeterQuill/Star-Lord,DaveBautistaasD Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor




comprehensive

author：focus    Page View：358
Alastair Grant/AP

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

advertisement

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Neuroscience startup Neumora files for IPO
Next article： Continuity nursing helped my family in our darkest PICU moments